ResearcherUniversity of CambridgeNo recent work listed
Frances M. Richards
Matched on ORCID iD 0000-0001-7947-7853; OpenAlex author ID A5017425394. Sources: OpenAlex.
Their work
- Papers
- 12 (first author 3, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 48
2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper
Papers 12
- Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinom… Co-author DOI 10.1136/jitc-2022-006457↗
- Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging. First author DOI 10.1021/acs.analchem.1c04579↗
- Size-tuneable and immunocompatible polymer nanocarriers for drug delivery in pancreatic cancer. Co-author DOI 10.1039/d2nr00864e↗
- Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment. Co-author DOI 10.1158/0008-5472.can-20-3807↗
- T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Canc… Co-author DOI 10.1158/1535-7163.mct-20-0620↗
- Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models. Co-author DOI 10.1038/s41416-020-1016-2↗
- Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. Co-author DOI 10.1016/j.ebiom.2019.01.037↗
- The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression. Co-author DOI 10.1158/1535-7163.mct-18-0010↗
- Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. Co-author DOI 10.1002/path.4727↗
- Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo. Last author DOI 10.1038/bjc.2014.288↗
- Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. First author DOI 10.1371/journal.pone.0067330↗
- Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells. First author DOI 10.1038/bjc.2012.450↗
Closest collaborators
The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Duncan Ian Jodrell · 10 shared papers, 2012–2023 · strength 0.86
- Paper Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenviro… DOI 10.1136/jitc-2022-006457↗
- Paper Size-tuneable and immunocompatible polymer nanocarriers for drug delivery in pancreatic cancer. DOI 10.1039/d2nr00864e↗
- Paper Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic … DOI 10.1038/s41416-020-1016-2↗
- Yann Wallez · 3 shared papers, 2018–2022 · strength 0.30
- Paper Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic … DOI 10.1038/s41416-020-1016-2↗
- Paper Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multim… DOI 10.1021/acs.analchem.1c04579↗
- Paper The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma R… DOI 10.1158/1535-7163.mct-18-0010↗
- Charles R. Dunlop · 3 shared papers, 2018–2022 · strength 0.30
- Paper Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic … DOI 10.1038/s41416-020-1016-2↗
- Paper Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multim… DOI 10.1021/acs.analchem.1c04579↗
- Paper The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma R… DOI 10.1158/1535-7163.mct-18-0010↗
- Tashinga E. Bapiro · 5 shared papers, 2012–2021 · strength 0.26
- Paper T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation o… DOI 10.1158/1535-7163.mct-20-0620↗
- Paper Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. DOI 10.1002/path.4727↗
- Paper Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo. DOI 10.1038/bjc.2014.288↗
- Brajesh Pratap Kaistha · 2 shared papers, 2022–2023 · strength 0.25
- Paper Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenviro… DOI 10.1136/jitc-2022-006457↗
- Paper Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multim… DOI 10.1021/acs.analchem.1c04579↗
- Rebecca J. Brais · 2 shared papers, 2022–2023 · strength 0.25
- Paper Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenviro… DOI 10.1136/jitc-2022-006457↗
- Paper Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multim… DOI 10.1021/acs.analchem.1c04579↗
- Albrecht Neeße · 3 shared papers, 2013–2019 · strength 0.15
- Paper Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intr… DOI 10.1016/j.ebiom.2019.01.037↗
- Paper Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo. DOI 10.1038/bjc.2014.288↗
- Paper Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. DOI 10.1371/journal.pone.0067330↗
- Vincenzo Graziano · 1 shared paper, 2023 · strength 0.14
- Jennifer P. Morton · 1 shared paper, 2023 · strength 0.14
- James E. D. Thaventhiran · 1 shared paper, 2023 · strength 0.14
- Andrea Bistrović · 1 shared paper, 2022 · strength 0.14
- Francesca Melle · 1 shared paper, 2022 · strength 0.14
- Ljiljana Fruk · 1 shared paper, 2022 · strength 0.14
- David Fairen‐Jiménez · 1 shared paper, 2022 · strength 0.14
- Marina Roy-Luzarraga · 1 shared paper, 2022 · strength 0.12
- Kairbaan Hodivala‐Dilke · 1 shared paper, 2022 · strength 0.12
- Victoria Sanz‐Moreno · 1 shared paper, 2022 · strength 0.12
- Ping‐Pui Wong · 1 shared paper, 2022 · strength 0.12
- Dieter Saur · 1 shared paper, 2022 · strength 0.12
- Simon T. Barry · 1 shared paper, 2022 · strength 0.11
- Nicole Strittmatter · 1 shared paper, 2022 · strength 0.11
- Aarthi Gopinathan · 1 shared paper, 2022 · strength 0.11
- Owen James Sansom · 1 shared paper, 2022 · strength 0.11
- Dandan Li · 1 shared paper, 2021 · strength 0.10
- Yaroslav Teper · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.